Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
ID: CHEMBL4052774
Journal: Bioorg Med Chem
Title: Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
Authors: Ibrahim MK, Eissa IH, Alesawy MS, Metwaly AM, Radwan MM, ElSohly MA.
Abstract: Peroxisome proliferator-activated receptor gamma (PPARγ) and sulfonylurea receptor (SUR) play crucial roles in management of type-2 diabetes mellitus. In this study, a series of novel quinazoline-4(3H)-one-sulfonylurea hybrids were designed and synthesized as dual PPARγ and SUR agonists. The synthesized compounds were evaluated for their in vivo anti-hyperglycemic activities against STZ-induced hyperglycemic rats. Four compounds (19a, 19d, 19f and 25g) demonstrated potent activities with reduction in blood glucose levels of 40.43, 46.42, 41.23 and 42.50 %, respectively. The most active ten compounds were further evaluated in vitro for their PPARγ binding affinities and insulin-secreting abilities. Compounds 19b, 19d, 19f, 25f and 25g exhibited the highest affinities against PPARγ with IC50 values of 0.371, 0.350, 0.369, 0.408 and 0.353µM, respectively. In addition, compounds 19d, 19f, and 25d showed the highest insulin-secreting activities with EC50 values of 0.97, 1.01 and 1.15µM, respectively. Furthermore, molecular docking and pharmacophore generation techniques were carried out to investigate binding patterns and fit values of the designed compounds with PPARγ and SUR, respectively. Also, two QSAR models were generated to explore the structural requirements controlling the different biological activities of the synthesized compounds against PPARγ and SUR.
CiteXplore: 28720328
Patent ID: ---
| ChEMBL ID | Target Similarity | Compound Similarity | Reference | Title | PubMed ID | DOI |
|---|---|---|---|---|---|---|
| CHEMBL1148467 | 1 | 0.01 | J Med Chem (2004) 47:196-209 | Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model. | 14695833 | 10.1021/jm0301888 |
| CHEMBL1131297 | 1 | 0 | J Med Chem (1998) 41:5055-5069 | N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. | 9836622 | 10.1021/jm980414r |
| CHEMBL4014320 | 1 | 0 | J Med Chem (2017) 60:4584-4593 | Structure-Activity Relationship of 2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) Analogs for PPARγ-Targeted Antidiabetics. | 28485590 | 10.1021/acs.jmedchem.6b01727 |
| CHEMBL4270651 | 1 | 0.02 | Eur J Med Chem (2018) 158:334-352 | Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor. | 30223121 | 10.1016/j.ejmech.2018.08.082 |
Assay Summary
Total
5
F - Functional
B - Binding
Bioactivity Summary
Total
72
IC50
Activity
EC50
ChEMBL is part of the ELIXIR infrastructure
ChEMBL is and Elixir Core Data Resource
Learn More
ChEMBL is a Global Core Biodata Resource